Over 2 years, bulevirtide monotherapy reduced the risk for decompensation and mortality, but not hepatocellular carcinoma, among patients with hepatitis D virus and compensated cirrhosis compared with untreated patients. “Bulevirtide, the first-in-class entry inhibitor, has been approved by EMA for treatment of compensated chronic hepatitis delta,” Elisabetta Degasperi, MD,
Milan
Lombardia
Italy
Kristen-dowd
Bykate-burba
Granda-ospedale-maggiore-policlinico